Der «Tiger im Tank»: Anti-VEGF-Langzeittherapie der neovaskulären AMD mit dem Port-Delivery-System

Karger Kompass Ophthalmologie ◽

10.1159/000519082 ◽

2021 ◽

pp. 1-3

Author(s):

Lars-Olof Hattenbach ◽

Armin Wolf

Keyword(s):

Delivery System ◽

Anti Vegf

Das Port-Delivery-System (PDS) mit Ranibizumab ist ein permanentes, nachfüllbares Augenimplantat in der Größe eines Reiskorns, das so konzipiert ist, dass es im Laufe der Zeit kontinuierlich Ranibizumab in das Auge abgibt. Ranibizumab ist ein Inhibitor des vaskulären endothelialen Wachstumsfaktors (VEGF), das eine entscheidende Rolle bei der Bildung neuer Blutgefäße und Gefäßleckagen spielt.

Download Full-text

Faculty Opinions recommendation of A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726140128.793518425 ◽

2016 ◽

Author(s):

Michael Singer ◽

Lyndon Tyler

Keyword(s):

Macular Edema ◽

Diabetic Macular Edema ◽

Delivery System ◽

Randomized Controlled Study ◽

Controlled Study ◽

Randomized Controlled ◽

Anti Vegf ◽

Persistent Diabetic Macular Edema

Download Full-text

New Anti-VEGF Drugs in Ophthalmology

Current Drug Targets ◽

10.2174/1389450121666200428101738 ◽

2020 ◽

Vol 21 (12) ◽

pp. 1194-1200

Author(s):

Claudio Campa

Keyword(s):

Clinical Trials ◽

Delivery System ◽

Clinical Development ◽

Advanced Stage ◽

Phase 3 ◽

Anti Vegf

: This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. : Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.

Download Full-text

Thermo-responsive hydrogel as an anti-VEGF drug delivery system to inhibit retinal angiogenesis in Rex rabbits

Technology and Health Care ◽

10.3233/thc-199015 ◽

2019 ◽

Vol 27 ◽

pp. 153-163 ◽

Cited By ~ 1

Author(s):

Chao-Chien Hu ◽

Yin-Chen Chiu ◽

Jen-Ray Chaw ◽

Chin-Fu Chen ◽

Hsia-Wei Liu

Keyword(s):

Drug Delivery ◽

Drug Delivery System ◽

Delivery System ◽

Anti Vegf ◽

Retinal Angiogenesis

Download Full-text

A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY

Retina ◽

10.1097/iae.0000000000000533 ◽

2015 ◽

Vol 35 (8) ◽

pp. 1604-1614 ◽

Cited By ~ 35

Author(s):

Raj K. Maturi ◽

Laura Bleau ◽

Jeffrey Saunders ◽

Mohamed Mubasher ◽

Michael W. Stewart

Keyword(s):

Macular Edema ◽

Diabetic Macular Edema ◽

Delivery System ◽

Randomized Controlled Study ◽

Controlled Study ◽

Randomized Controlled ◽

Anti Vegf ◽

Persistent Diabetic Macular Edema

Download Full-text

A Novel Anti-VEGF Targeting and MRI-Visible Smart Drug Delivery System for Specific Diagnosis and Therapy of Liver Cancer

Macromolecular Bioscience ◽

10.1002/mabi.201300137 ◽

2013 ◽

Vol 13 (10) ◽

pp. 1358-1368 ◽

Cited By ~ 14

Author(s):

Hailong Huang ◽

Yapeng Li ◽

Caijin Li ◽

Yuzhen Wang ◽

Yuan Sun ◽

...

Keyword(s):

Drug Delivery ◽

Liver Cancer ◽

Drug Delivery System ◽

Delivery System ◽

Specific Diagnosis ◽

Diagnosis And Therapy ◽

Anti Vegf ◽

Smart Drug ◽

Smart Drug Delivery

Download Full-text

Evaluation of Port Delivery System with ranibizumab for the treatment of neovascular age-related macular degeneration

Therapeutic Delivery ◽

10.4155/tde-2020-0132 ◽

2021 ◽

Vol 12 (3) ◽

pp. 191-200

Author(s):

Annika J Patel ◽

Dante J Pieramici ◽

Nika Bagheri

Keyword(s):

Macular Degeneration ◽

Delivery System ◽

Current Treatment ◽

Age Related Macular Degeneration ◽

Office Visits ◽

Continuous Release ◽

Anti Vegf ◽

Age Related ◽

Pars Plana

Current treatment of neovascular age-related macular degeneration involves periodic intravitreal injections of anti-VEGF medication, creating a burden to patients and physicians, resulting in nonadherence to recommended dosing schedules. The Port Delivery System with ranibizumab offers a long-term solution that involves implantation of a device into the pars plana and provides continuous release of anti-VEGF medication into the vitreous, thus requiring fewer office visits. The Port Delivery System has demonstrated comparable visual and anatomic outcomes to monthly injections and shows promise in alleviating the patient burden in the treatment of neovascular age-related macular degeneration, making possible better long-term real-world visual outcomes.

Download Full-text